La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Clovis Oncology Salute del bilancio
Salute finanziaria criteri di controllo 0/6
Clovis Oncology has a total shareholder equity of $-417.9M and total debt of $660.4M, which brings its debt-to-equity ratio to -158%. Its total assets and total liabilities are $346.8M and $764.7M respectively.
Informazioni chiave
-158.0%
Rapporto debito/patrimonio netto
US$660.38m
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | US$58.32m |
| Patrimonio netto | -US$417.89m |
| Totale passività | US$764.66m |
| Totale attività | US$346.78m |
Aggiornamenti recenti sulla salute finanziaria
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05Analisi della posizione finanziaria
Passività a breve termine: CLVS.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passività a lungo termine: CLVS.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: CLVS.Q has negative shareholder equity, which is a more serious situation than a high debt level.
Riduzione del debito: CLVS.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: Insufficient data to determine if CLVS.Q has enough cash runway based on its current free cash flow.
Previsione Cash Runway: Insufficient data to determine if CLVS.Q has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.